These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20053923)

  • 21. Identification of natural coumarin compounds that rescue defective DeltaF508-CFTR chloride channel gating.
    Xu LN; Na WL; Liu X; Hou SG; Lin S; Yang H; Ma TH
    Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):878-83. PubMed ID: 18430055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corrector combination therapies for F508del-CFTR.
    Hanrahan JW; Matthes E; Carlile G; Thomas DY
    Curr Opin Pharmacol; 2017 Jun; 34():105-111. PubMed ID: 29080476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Progress in the Discovery and Development of Small-Molecule Modulators of CFTR.
    Kym PR; Wang X; Pizzonero M; Van der Plas SE
    Prog Med Chem; 2018; 57(1):235-276. PubMed ID: 29680149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis.
    Phuan PW; Yang B; Knapp JM; Wood AB; Lukacs GL; Kurth MJ; Verkman AS
    Mol Pharmacol; 2011 Oct; 80(4):683-93. PubMed ID: 21730204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling.
    Sondo E; Tomati V; Caci E; Esposito AI; Pfeffer U; Pedemonte N; Galietta LJ
    Am J Physiol Cell Physiol; 2011 Oct; 301(4):C872-85. PubMed ID: 21753184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR.
    Bose SJ; Bijvelds MJC; Wang Y; Liu J; Cai Z; Bot AGM; de Jonge HR; Sheppard DN
    Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L71-L86. PubMed ID: 30969810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ivacaftor potentiation of multiple CFTR channels with gating mutations.
    Yu H; Burton B; Huang CJ; Worley J; Cao D; Johnson JP; Urrutia A; Joubran J; Seepersaud S; Sussky K; Hoffman BJ; Van Goor F
    J Cyst Fibros; 2012 May; 11(3):237-45. PubMed ID: 22293084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of thiazole derivatives on basic defects underlying cystic fibrosis.
    Pesce E; Pedemonte N; Leoni A; Locatelli A; Morigi R
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127473. PubMed ID: 32784089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening.
    Kalid O; Mense M; Fischman S; Shitrit A; Bihler H; Ben-Zeev E; Schutz N; Pedemonte N; Thomas PJ; Bridges RJ; Wetmore DR; Marantz Y; Senderowitz H
    J Comput Aided Mol Des; 2010 Dec; 24(12):971-91. PubMed ID: 20976528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A chemical corrector modifies the channel function of F508del-CFTR.
    Kim Chiaw P; Wellhauser L; Huan LJ; Ramjeesingh M; Bear CE
    Mol Pharmacol; 2010 Sep; 78(3):411-8. PubMed ID: 20501743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms.
    Roxo-Rosa M; Xu Z; Schmidt A; Neto M; Cai Z; Soares CM; Sheppard DN; Amaral MD
    Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17891-6. PubMed ID: 17098864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR.
    Moniz S; Sousa M; Moraes BJ; Mendes AI; Palma M; Barreto C; Fragata JI; Amaral MD; Matos P
    ACS Chem Biol; 2013 Feb; 8(2):432-42. PubMed ID: 23148778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repairing the basic defect in cystic fibrosis - one approach is not enough.
    Farinha CM; Matos P
    FEBS J; 2016 Jan; 283(2):246-64. PubMed ID: 26416076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
    Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
    Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of ΔF508- and G551D-CFTR-Mediated Cl- Current by Novel Hydroxypyrazolines.
    Park J; Khloya P; Seo Y; Kumar S; Lee HK; Jeon DK; Jo S; Sharma PK; Namkung W
    PLoS One; 2016; 11(2):e0149131. PubMed ID: 26863533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Butyl-p-hydroxybenzoate stimulates cystic fibrosis transmembrane conductance regulator Cl- transport].
    Ge H; Hou TT; Sun JJ; Yang H
    Yao Xue Xue Bao; 2009 Jan; 44(1):32-7. PubMed ID: 19350818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-activity relationship of 1,4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel.
    Pedemonte N; Boido D; Moran O; Giampieri M; Mazzei M; Ravazzolo R; Galietta LJ
    Mol Pharmacol; 2007 Jul; 72(1):197-207. PubMed ID: 17452495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unravelling druggable signalling networks that control F508del-CFTR proteostasis.
    Hegde RN; Parashuraman S; Iorio F; Ciciriello F; Capuani F; Carissimo A; Carrella D; Belcastro V; Subramanian A; Bounti L; Persico M; Carlile G; Galietta L; Thomas DY; Di Bernardo D; Luini A
    Elife; 2015 Dec; 4():. PubMed ID: 26701908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
    Birault V; Solari R; Hanrahan J; Thomas DY
    Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.